Match!

Value creation and sharing among universities, biotechnology and pharma.

Published on Jun 1, 2003in Nature Biotechnology31.864
· DOI :10.1038/nbt0603-618
Mark G Edwards2
Estimated H-index: 2
,
Fiona Murray24
Estimated H-index: 24
(MIT: Massachusetts Institute of Technology),
Robert Yu2
Estimated H-index: 2
Abstract
An analysis of deal structures in biotechnology from the past 25 years reveals that universities often neglect important economic aspects in their licensing agreements.
  • References (0)
  • Citations (53)
📖 Papers frequently viewed together
6,158 Citations
509 Citations
3,045 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References0
Newest
Cited By53
Newest
#1V.J. Thomas (UFV: University of the Fraser Valley)H-Index: 5
#2Martin J. Bliemel (UTS: University of Technology, Sydney)H-Index: 7
Last. Elicia Maine (SFU: Simon Fraser University)H-Index: 12
view all 4 authors...
Abstract University spin-offs are important mechanisms for creating and capturing value from scientific inventions. Academic scientists are uniquely positioned to shape such opportunities long before the university spin-off is founded. To better understand how science-based university spin-offs can be endowed for success, the pre-formation stage of 30 ventures co-founded over a 40 year period by a star-scientist-entrepreneur is analysed by matching his 363 co-invented US patents granted to 1476 ...
Source
Source
In the domain of technology startups, biotechnology has often been considered as specific. Their unique technology content, the type of founders and managers they have, the amount of venture capital they raise, the time it takes them to reach an exit as well as the technology clusters they belong to are seen as such unique features. Based on extensive research from new databases, the author claims that the biotechnology startups are not as different as it might have been claimed: the amount of v...
Source
Source
#1Panos Lehouritis (UCC: University College Cork)H-Index: 7
#2Glenn Hogan (UCC: University College Cork)H-Index: 1
Last. Mark Tangney (UCC: University College Cork)H-Index: 26
view all 3 authors...
Abstract Bacterial-directed enzyme prodrug therapy (BDEPT) is an emerging form of treatment for cancer. It is a biphasic variant of gene therapy in which a bacterium, armed with an enzyme that can convert an inert prodrug into a cytotoxic compound, induces tumour cell death following tumour-specific prodrug activation. BDEPT combines the innate ability of bacteria to selectively proliferate in tumours, with the capacity of prodrugs to undergo contained, compartmentalised conversion into active m...
6 CitationsSource
#1Charlotta Dahlborg (KI: Karolinska Institutet)H-Index: 1
#2Danielle Lewensohn (KI: Karolinska Institutet)H-Index: 1
Last. Carl Johan Sundberg (KI: Karolinska Institutet)H-Index: 33
view all 4 authors...
Abstract Numerous papers on university patenting and commercialisation have mapped the patent ownership landscape at a variety of academic institutions. Despite these efforts, there is still a scarcity in empirical evidence in terms of how patented academic inventions are commercialised over time. This paper extends previous work on academic commercialisation by tracing patent ownership transfers longitudinally. We develop a conceptual framework of academic patent transfer modes that distinguish...
4 CitationsSource
ABSTRACTThis paper discusses how small technology-based firms (STBFs) effectively manage vertical alliances by choosing proper alliance structures to both manage challenges and pursue higher performance. We consider the main challenges of STBFs’ vertical alliances as opportunistic risk and coordination concern between partners, and derive four types of vertical alliance portfolios with different extents of risk and return based on the relational perspective. We then examine the impact of each po...
2 CitationsSource
Source
In recent years, there has been substantial interest in the potential value of collaboration between academia and the pharmaceutical industry. In this Crosstalk, I discuss obstacles to these relationships being optimally productive.
2 CitationsSource
#1Kenneth FernaldH-Index: 1
markdownabstractAbstract Improving medicine and health is the ultimate purpose of biotechnological innovation, where basic science is used to develop new innovative diagnostics and therapeutics to significantly improve the lives of patients worldwide. Concurrently, for three stakeholder groups, the primary goal is to generate profitable business from biotechnological innovation. These stakeholders are ‘entrepreneurial’ biotech companies, venture capitalists and established pharmaceutical firms. ...
4 Citations